Dr Tricia Brown, MD, FAAD:
Treatment testimonial video
Transcript
I am Tricia Brown, a board-certified dermatologist in Woodlands, TX, and this is my experience.
I began prescribing KLISYRI® because I frequently prescribe field therapy for actinic damage. I have found though, that many patients will return completely untreated because they are concerned about the downtime and the process involved. However, with KLISYRI®, the downtime is minimal… the process is really easy for them. I have found that KLISYRI® is a treatment they will actually follow through with.
The type of patient who would benefit most from KLISYRI®, to me, would be someone with localized face or scalp involvement because this shouldn’t significantly impact their appearance, and they shouldn’t have significant downtime with this short treatment.
I have used KLISYRI® so that I could first experience the process and then be able to better describe it to my patients. I really get excited when I can find a treatment that is both effective and manageable for patients and that’s when I can get patients on board.
INDICATION
KLISYRI is a microtubule inhibitor indicated for the topical treatment of actinic keratosis of the face or scalp
IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
Ophthalmic Adverse Reactions
KLISYRI may cause eye irritation. Avoid transfer of the drug into the eyes and to the periocular area during and after application. Wash hands immediately after application. If accidental exposure occurs, instruct patient to flush eyes with water and seek medical care as soon as possible
Local Skin Reactions
Local skin reactions, including severe reactions (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration) in the treated area can occur after topical application of KLISYRI. Occlusion after topical application of KLISYRI is more likely to result in irritation. Avoid use until skin is healed from any previous drug, procedure, or surgical treatment.
ADVERSE REACTIONS
The most common adverse reactions (incidence ≥2%) were local skin reactions, application site pruritus, and application site pain.
Please see full Prescribing Information.
References: 1. KLISYRI®. Prescribing information. Almirall, LLC. 2. Blauvelt A, Kempers S, Lain E, et al. Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis. N Engl J Med. 2021;384:512-520.
KLISYRI® is a registered trademark of Almirall, LLC.
© 2005-2022
All Rights Reserved.
Almirall, LLC. 101 Lindenwood Drive, Ste 400, Malvern, PA 19355
US-TIRBA-2200008 09/2022
IMPORTANT SAFETY INFORMATION
INDICATION
KLISYRI is a microtubule inhibitor indicated for the topical field treatment of actinic keratosis on the face or scalp.
IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
Ophthalmic Adverse Reactions
KLISYRI may cause eye irritation. Avoid transfer of the drug into the eyes and to the periocular area during and after application. Wash hands immediately after application. If accidental exposure occurs, instruct patient to flush eyes with water and seek medical care as soon as possible.
Local Skin Reactions
Local skin reactions, including severe reactions (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration) in the treated area can occur after topical application of KLISYRI. Occlusion after topical application of KLISYRI is more likely to result in irritation. Avoid use until skin is healed from any previous drug, procedure, or surgical treatment.
ADVERSE REACTIONS
The most common adverse reactions (incidence ≥2%) were local skin reactions, application site pruritus, and application site pain.
Please see full Prescribing Information.
To report an adverse event or product complaint, call or email Medical Affairs and Customer Relations • Phone: 1-866-665-2782• Fax: 510-595-8183 •
Email: almirallmc@eversana.com